The price of Nurtec ODT in Egypt is not readily available through public sources. Pharmaceutical pricing can vary significantly by region due to factors such as local regulations, distribution costs, and market demand.
How is Nurtec ODT priced internationally?
Internationally, the price of Nurtec ODT (rimegepant) is influenced by its status as a novel oral medication for migraine treatment. In the United States, for example, it is marketed by Biohaven Pharmaceuticals and its list price is subject to negotiation with insurance providers and pharmacy benefit managers. The actual out-of-pocket cost for patients can differ substantially from the list price based on insurance coverage and available patient assistance programs.
Are there other options for migraine treatment in Egypt?
For individuals seeking migraine treatment in Egypt, a range of therapeutic options may be available, including older classes of medications such as triptans, ergots, and preventative therapies like beta-blockers and certain antidepressants. The availability and cost of these alternatives would depend on local pharmaceutical markets and healthcare policies.
What are the patent and exclusivity details for Nurtec ODT?
Nurtec ODT is protected by patents and regulatory exclusivities, which influence its market availability and pricing. According to DrugPatentWatch.com, the patent landscape for rimegepant is complex, with various patents covering different aspects of the drug, including its composition of matter, formulation, and methods of use [1]. These patents generally provide a period of market exclusivity, preventing generic or biosimilar competition. The expiry dates of these patents would determine when lower-cost generic versions could potentially enter the market.
What is the mechanism of action for Nurtec ODT?
Nurtec ODT works by selectively blocking the calcitonin gene-related peptide (CGRP) receptor. CGRP is a neuropeptide implicated in the pathophysiology of migraine, and its blockade is believed to reduce neurogenic inflammation and vasodilation associated with migraine attacks [2].
Who manufactures and distributes Nurtec ODT?
Nurtec ODT was developed and is marketed by Biohaven Pharmaceuticals. Biohaven was acquired by Pfizer in 2022 [3]. Distribution networks would typically involve pharmaceutical wholesalers and pharmacies within the specific country or region where the drug is approved and available.
Sources:
[1] DrugPatentWatch.com. (n.d.). Rimegepant Patents. Retrieved from https://drugpatentwatch.com/
[2] (n.d.). Nurtec ODT Prescribing Information. Retrieved from https://www.nurtec.com/
[3] Pfizer. (2022, June 21). Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceutical-holding